SCHEMBL9890695

SCHEMBL9890695

COC(=O)C(O)c1cc(F)ccc1-c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 2/20 0.41
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
NR3C2 P08235 2/20 0.39
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TACR3 P29371 1/20 0.38
GPBAR1 Q8TDU6 1/20 0.38
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890656 0.87 CES2 (0.42) CHRM3CES2CES1MEN1KMT2A
SCHEMBL9890699 0.86 CTSA (0.41) CHRM3PSEN1PSEN2APH1BNCSTN
SCHEMBL9890694 0.84 SLC6A4 (0.42) CHRM3PSEN1PSEN2APH1BNCSTN
SCHEMBL9890804 0.81 CES2 (0.42) CES2CES1MAPTDHODH
SCHEMBL9890696 0.81 RPS6KB1 (0.41) CHRM3PSEN1PSEN2APH1BNCSTN
SCHEMBL9890693 0.78 NR3C2 (0.44) CHRM3PSEN1PSEN2APH1BNCSTN
SCHEMBL8595608 0.77 CES2 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6400373 0.77 CES2 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8410789 0.77 CES2 (0.56) CES2CES1MEN1KMT2A
SCHEMBL7522990 0.77 CES2 (0.56) CES2CES1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM3 298/4885PSEN1 2126/4885PSEN2 1867/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM3 298/4885PSEN1 2126/4885PSEN2 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.